Drug Trial Radar · NCT03269994
Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?
Last checked: Nov 20, 2026Latest source record: Oct 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
967
Actual
Start
Nov 21, 2017
Primary completion
Jan 28, 2025
Study completion Jan 28, 2025
Sponsor
- Lead sponsor
- Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Indiana University; Massachusetts General Hospital; Thomas Jefferson University; Washington University School of Medicine; Advocate Illinois Masonic Medical Center; Baptist Memorial Health Care Corporation; Baylor Scott and White Health; The Cleveland Clinic; Emory University; Fox Chase Cancer Center; Gundersen Lutheran Medical Center; Hackensack Meridian Health; Hamilton Health Sciences Center; Intermountain Health Care, Inc.; Jersey Shore Medical Center (Hackensack Meridian); Johns Hopkins University; Montefiore Medical Center/Albert Einstein College of Medicine; North Shore University HealthSystem; Milton S. Hershey Medical Center; Rhode Island Hospital; Stony Brook Medicine; Sunnybrook Health Sciences Centre; Temple University; Ohio State University; The Ottowa Hospital/University of Ottowa; University of California, Davis; University of Chicago; University of Iowa; University of Texas Southwestern Medical Center; University of Utah; University of Wisconsin, Madison; Providence Health & Services; Albany Medical College; Northwestern University; Universtiy of Mississippi Medical Center; Mount Sinai Hospital, New York; Brody School of Medicine at East Carolina University
- First posted
- Sep 1, 2017
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to figure out which commonly used antibiotic, cefoxitin or piperacillin-tazobactam, is better at decreasing the rate of surgical site infections after pancreatoduodenectomy.
Conditions
- Pancreatic Cancer
- Pancreas Cancer
- Pancreatic Diseases
Interventions
CefoxitinDrug
Participants will receive one dose of cefoxitin within 1 hour of incision time, redosed every 2-4 hours in the operating room until closure of the incision, and discontinued within 24 hours after anesthesia end time.
Piperacillin-tazobactamDrug
Participants will receive one dose of piperacillin-tazobactam within 1 hour of incision time, redosed every 2-4 hours in the operating room until closure of the incision, and discontinued within 24 hours after anesthesia end time.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Evaluated for the Effectiveness of Cefoxitin as a Surgical Antibiotic Prophylaxis.Time frame: 30 days
Locations
32 sites in 2 countries. Site status is shown where the registry gives one.
UC Davis Comprehensive Cancer Center
Sacramento, California
Emory University School of Medicine
Atlanta, Georgia
Northwestern Medicine (Data Collection)
Chicago, Illinois
NorthShore University Health System
Evanston, Illinois
Indiana University
Indianapolis, Indiana
University of Iowa
Iowa City, Iowa
Massachusetts General Hospital
Boston, Massachusetts
University of Washington School of Medicine
St Louis, Missouri
University of Nebraska Medical Center
Omaha, Nebraska
Memorial Sloan Kettering Basking Ridge (Consent only)
Basking Ridge, New Jersey
Hackensack Meridian Health / Hackensack University Medical Center Cancer Center
Hackensack, New Jersey
Memorial Sloan Kettering Commack (Consent only)
Commack, New York
Memoral Sloan Kettering Westchester (Consent only)
Harrison, New York
Mount Sinai Hospital
New York, New York
Mount Sinai West
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Montefiore Health Systems (Montefiore Medical Center)
The Bronx, New York
Duke University
Durham, North Carolina
Brody School of Medicine at East Carolina University
Greenville, North Carolina
Ohio State University
Columbus, Ohio
Providence Health & Services (Portland Med Ctr)
Portland, Oregon
Pennsylvania State Hershey
Hershey, Pennsylvania
Thomas Jefferson University Hospital
Philadelphia, Pennsylvania
Baptist Memorial Healthcare
Memphis, Tennessee
Baylor Scott & White Health
Dallas, Texas
Intermountain Healthcare
Murray, Utah
University of Utah
Salt Lake City, Utah
Gundersen Lutheran Medical Foundation
La Crosse, Wisconsin
University of Wisconsin
Madison, Wisconsin
Hamilton Health Sciences Center (Juravinski Hospital)
Hamilton, Ontario, Canada
Ottawa Hospital
Ottawa, Ontario, Canada
Sunnybrook Health Sciences Centre
Toronto, Ontario, Canada
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.